Clicky

Revelation Biosciences, Inc.(REVB)

Description: Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.


Keywords: Clinical Medicine Disease Immunology Infection Vaccination Respiratory Diseases Allergic Rhinitis Rhinitis Allergology Nasal Administration Same Technology

Home Page: www.revbiosciences.com

REVB Technical Analysis

4660 La Jolla Village Drive
San Diego, CA 92122
United States
Phone: 650-800-3717


Officers

Name Title
Mr. James M. Rolke CEO & Director
Mr. Chester Stanley Zygmont III Chief Financial Officer
Ms. Sandra Vedrick VP of HR & Investor Relations
Ms. Carol Odle Sr. Director of Clinical Projects

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 7.7942
Trailing PE: 0
Price-to-Book MRQ: 0.8909
Price-to-Sales TTM: 2.8821
IPO Date: 2020-11-17
Fiscal Year End: December
Full Time Employees: 14
Back to stocks